Prostate Cancer
Conditions
Keywords
Molecular Imaging, PSMA, adenocarcinoma, prostatectomy
Brief summary
This is a single arm, open label study of up to 20 patients with prostate cancer scheduled for prostatectomy at the NIH Clinical Center. 123I-MIP-1072 image data will be evaluated for visible uptake and compared with histopathology.
Detailed description
This is an exploratory, single arm, open label pilot study evaluation of 123I-MIP-1072 intraprostatic uptake determination by SPECT/CT imaging (and optional CGCP imaging), with histological confirmation of disease localization and staging. Methodical evaluation of 123I-MIP-1072 in intraprostatic tumorous and non-tumours regions will provide important preliminary data upon which further clinical studies can be based. The optional additional CGCP imaging was added, because of its inherent potential for higher resolution scintigraphic detection of 123I-MIP-1072 localization. This imaging feasibility data will provide important preliminary information for the use of CGCP imaging in prostate cancer.
Interventions
DRUG123I-MIP-1072
Single IV dose
Sponsors
National Cancer Institute (NCI)
Molecular Insight Pharmaceuticals, Inc.
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Participant must be scheduled to undergo standard of care prostatectomy for presumed localized prostate cancer at the NIH Clinical Center. * Have had or will undergo multiparametric endorectal coil 3T MR at the NIH clinical center * Recent (within 12 months of study entry) trans-rectal biopsy indicating the presence of adenocarcinoma of the prostate gland * Participant must be 18 years or older. * ECOG Performance grade of 0 to 2. (see Appendix 1) * Ability to understand and provide informed consent. All subjects must sign a document of informed consent indicating their understanding of the investigational nature and risks of the study before any protocol related studies are performed. * Participants of childbearing potential must agree to use an acceptable form of birth control, defined as abstinence, barrier or other acceptable, effective contraceptive method until 7 days after the infusion of study drug.
Exclusion criteria
* Participants for whom participating would significantly delay the scheduled standard of care therapy. * Subjects must not have prostate biopsies performed within 12 weeks before imaging; or within 8 weeks before imaging providing that the absence of hemorrhage is confirmed by MR imaging. * SGOT and SGPT ≥ 2 x of the upper limits of normal; total bilirubin, of ≥ 1.5 x the upper limits of normal or ≥ 3.0 mg/dl in patients with Gilbert's syndrome. * Administered a radioisotope within 5 physical half lives prior to study enrollment. * Patients with severe claustrophobia unresponsive to oral anxiolytics * Subjects weighing ≥350 lbs or are unable to fit within the imaging gantry * Subjects who have received androgen deprivation therapy. * Subjects with any medical condition or other circumstances that, in the opinion of the Investigator, would significantly decrease obtaining reliable data, achieving study objectives or completing the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the tissue distribution of 123I-MIP-1072 SPEC/CT imaging in tumor and non-tumorous regions of the prostate (as determined by histopathology) in patients undergoing standard of care prostatectomy | Evaulated through Day 30 |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate the potential of 123I-MIP-1072 imaging to predict malignancy as defined by histopathology and multiparametric 3T MR | Evaulated through Day 30 |
| To further evaluate the safety of 123I-MIP-1072 | Evaluated through Day 30 |
| To evaluate the intensity of 123I-MIP-1072 uptake with respect to Gleason Grade | Evaluated through Day 30 |
| To evaluate the intensity of 123I-MIP-1072 uptake with respect to PSMA expression | Evaluated through Day 30 |
| To evaluate feasibility of imaging123I-MIP-1072 uptake using an FDA-approved compact endorectal gamma camera probe (CGCP) | Evaluated through Day 30 |
Countries
United States
Outcome results
None listed